| 000 | 05165nas a22003735i 4500 | ||
|---|---|---|---|
| 001 | 2190-9164 | ||
| 003 | DE-He213 | ||
| 005 | 20200124155121.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 150723s||||||||xxkuu poo|||||| b|EN |d | ||
| 022 | _a2190-9164 | ||
| 024 | 7 |
_a10.1007/13554.2190-9164 _2doi |
|
| 210 | 1 | 0 | _aBiol Ther |
| 245 | 1 | 0 |
_aBiologics in Therapy _h[electronic resource]. |
| 264 | 1 |
_aCheshire : _bSpringer Healthcare : _bImprint: Adis. |
|
| 300 | _bonline resource. | ||
| 520 | _aPlease note: Biologics in Therapy is no longer accepting submissions. For information on our other journals or for any other enquiries please contact adisrapidplus@springer.com. Over recent years biotechnology has been instrumental in the development of key medicines such as monoclonal antibodies for the treatment of cancer and autoimmune conditions such as rheumatoid arthritis and psoriasis, human insulin for the treatment of diabetes, and the cloning of erythropoietin to stimulate the production of red blood cells in the treatment of chronic anemia. In this fast-paced area of medical research, we feel it is of utmost importance for specialist and generalist healthcare professionals alike to have access to the most up to date and relevant research, including analysis on how this research translates to treatment strategies in clinical practice. Each biological therapy has a highly sensitive and specific mode of action in relation to particular indications and therapy areas, and as such it was felt that research in these areas would be better suited to therapeutic area-specific journals, where data and information will gain optimal exposure and recognition in that particular field to the most relevant audience. In accordance with this approach, Biologics in Therapy will be closing at the end of 2015. The Adis journal portfolio continues to welcome content relating to the discovery, development, and use of biological and biosimilar therapies in all medical fields, including high-quality preclinical, clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of such therapies. Studies relating to diagnosis, pharmacoeconomics, public health, quality of life, and patient care, management, and education are also encouraged throughout the portfolio. ----- Biologics in Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality preclinical, clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of biological therapies. Studies relating to diagnosis, pharmacoeconomics, public health, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports, and short communications. The journal appeals to a global audience and receives submissions from all over the world. Moving forward from traditional publishing, Biologics in Therapy offers a range of additional enhanced features designed to increase visibility, readership, and the educational value of the content. Each paper is accompanied by a bulleted Summary slide, giving a time-efficient overview of the content to a wide readership. Articles also have the option to include slide sets, videos, animations, and/or interactive learning resources. All enhanced features are open access and are peer reviewed to the same high standard as the article itself. Biologics in Therapy is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/2.5. | ||
| 650 | 0 | _aInternal medicine. | |
| 650 | 0 | _aEndocrinology. | |
| 650 | 0 | _aGastroenterology. | |
| 650 | 0 | _aInfectious diseases. | |
| 650 | 0 | _aOncology. | |
| 650 | 0 | _aRheumatology. | |
| 650 | 1 | 4 |
_aInternal Medicine. _0http://scigraph.springernature.com/things/product-market-codes/H33002 |
| 650 | 2 | 4 |
_aOncology. _0http://scigraph.springernature.com/things/product-market-codes/H33160 |
| 650 | 2 | 4 |
_aRheumatology. _0http://scigraph.springernature.com/things/product-market-codes/H33170 |
| 650 | 2 | 4 |
_aGastroenterology. _0http://scigraph.springernature.com/things/product-market-codes/H33061 |
| 650 | 2 | 4 |
_aEndocrinology. _0http://scigraph.springernature.com/things/product-market-codes/H33053 |
| 650 | 2 | 4 |
_aInfectious Diseases. _0http://scigraph.springernature.com/things/product-market-codes/H33096 |
| 710 | 2 | _aSpringerLink (Online service) | |
| 776 | 0 | 8 |
_iPrinted version: _x2195-5840 |
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/13554.2190-9164 _zOpen Access |
| 999 |
_c513601 _d513599 |
||